References Arcangelo , V. P., & Peterson, A. M. (2013). Pharmacotherapeutics for Advanced Practice: A Practical Approach (3rd ed. (pp. 696-714). Ambler, PA: Lippincott Williams & Wilkins. Aman , M., Rettiganti , M., Nagaraja , H. N., Hollway , J. A., McCracken, J., McDougle , C. J., ... & Vitiello , B. (2015). Tolerability, Safety, and Benefits of Risperidone in Children and Adolescents with Autism: 21-Month Follow-up After 8-Week Placebo-Controlled Trial. Journal of child and adolescent psychopharmacology, 25(6 ), 482-493. Carbemazepine . Medscape Drugs and Diseases. Retrieved November 11, 2015 from http:// reference.medscape.com/drug/tegretol-xr-equetro- carbamazepine-343005 Filipek PA, Accardo PJ, Baranek GT, Cook EH, Dawson G, Gordon B, Gravel JS, Johnson CP, Kallen RJ, Levy SE, Minshew NJ, Ozonoff S, Prizant BM, Rapin I, Rogers SJ, Stone WL, Teplin S, Tuchman RF, Volkmar FR (1999). "The screening and diagnosis of autistic spectrum disorders". J Autism Dev Disord 29 (6): 439–84 . LLerena , A., Berecz , R., Peñas-LLedó , E., Süveges , Á., & Fariñas , H. (2013). Pharmacogenetics of clinical response to risperidone . Pharmacogenomics, 14(2 ), 177-194. Risperidone (2015). Medscape Drugs and Diseases. Retrieved November 11, 2015 from http:// reference.medscape.com/drug/risperdal-consta- risperidone-342986#10 Schatzberg , AF, Nemeroff , C . The American Psychiatric Publishing Textbook of Psychopharmacology. 4th ed.American Psychiatric Publishing, 2009.